TITLE

Tachykinins potently stimulate human small bowel blood flow: a laser Doppler flowmetry study in humans

AUTHOR(S)

Schmidt, P.T.; Lördal, M.; Gazelius, B.; Hellström, P.M.

PUB. DATE

January 2003

SOURCE

Gut;Jan2003, Vol. 52 Issue 1, p53

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: The two tachykinins substance P and neurokinin A are abundantly present in the gastrointestinal tract. Substance P preferring neurokinin 1 receptors are mainly found in submucosal blood vessels while neurokinin A preferring neurokinin 2 receptors seem to be confined to smooth muscle cells. Tachykinin effects on intestinal mucosal blood flow in humans are not known. Aim: To study the effects of substance P and neurokinin A on small bowel mucosal blood flow in humans. Methods: A manometry tube supplied with single fibre microprobes recorded mucosal blood flow in the proximal small bowel using laser Doppler flowmetry, concomitant with luminal manometry, defining phases I, II, and III of the migrating motor complex. Simultaneously, flowmetry of temporal skin was performed. Under fasting conditions saline was infused intravenously over four hours followed by infusion of substance P, neurokinin A, or saline. Results: During phase I, substance P 1-6 pmol/kg/min increased mucosal blood flow dose dependently by a maximum of 158%. Blood flow of the temporal skin increased in parallel. Neurokinin A 6-50 pmol/kg/min increased mucosal blood flow maximally by 86% at 25 pmol/kg/min while blood flow of temporal skin increased at alt doses. Substance P at all doses and neurokinin A at the highest dose only, increased pulse rate. Systolic blood pressure was unchanged by either peptide while substance P at the highest dose decreased diastolic pressure. Conclusion: Tachykinins increase blood flow of the small bowel and temporal skin. With substance P being more potent than neurokinin A, these effects are probably mediated through neurokinin 1 receptors.

ACCESSION #

9758405

 

Related Articles

• Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology. Improta, Giovanna; Broccardo, Maria // Current Drug Targets;Aug2006, Vol. 7 Issue 8, p1021 

  Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during...

• Anti-tumour activity of tachykinin NK1receptor antagonists on human glioma U373 MG xenograft. Palma, C; Bigioni, M; Irrissuto, C; Nardelli, F; Maggi, C A; Manzini, S // British Journal of Cancer;1/15/2000, Vol. 82 Issue 2, p480 

  Astrocytes harbour functional receptors to many neurotransmitters, including substance P (SP), an undecapeptide belonging to the tachykinin family of peptide transmitters. SP activates malignant glial cells to induce cytokine release and proliferation, both responses being relevant for tumour...

• Involvement of Tachykinins in Endotoxin-Induced Airway Hyperresponsiveness. Loeffler, B.S.; Arden, W.A.; Fiscus, R.R.; Lee, L.-Y. // Lung;1997, Vol. 175 Issue 4, p253 

  Inhaled endotoxin, lipopolysaccharide (LPS), has been shown to result in bronchial hyperresponsiveness (BHR) to endogenous bronchoconstrictive mediators such as histamine. To determine the role of sensory neuropeptides released from bronchopulmonary C-fibers in LPS-induced BHR, 24 guinea pigs...

• PreBötzinger complex (preBötC) neurokinin-1 receptor (NK1R) expressing neurons are required for eupnea in adult awake rats. Gray, P. A.; Janczewski, W. A.; Mellen, N.; McCrimmon, D. R.; Feldman, J. L. // Respiratory Research;2001 Supplement 1, Vol. 2, pS7 

  An abstract of the study "PreBötzinger complex (preBötC) neurokinin-1 receptor (NK1R) expressing neurons are required for eupnea in adult awake rats," by P.A. Gray and colleagues is presented.

• An FDA Approved Neurokinin-1 Receptor Antagonist is Effective in Reducing Intraabdominal Adhesions when Administered Intraperitoneally, But Not Orally. Lim, Rizal; Morrill, Jonathan M.; Prushik, Scott G.; Reed, Karen L.; Gower, Adam C.; Leeman, Susan E.; Stucchi, Arthur F.; Becker, James M. // Journal of Gastrointestinal Surgery;Jan2009, Vol. 13 Issue 1, p43 

  A correction to the article "An FDA Approved Neurokinin-1 Receptor Antagonist is Effective in Reducing Intraabdominal Adhesions When Administered Intraperitoneally, But Not Orally," by R. Lim et al. which appeared in a previous issue is presented.

• Neurokinin A.  // Encyclopedic Reference of Molecular Pharmacology;2004, p632 

  An encyclopedia entry for "neurokinin A" is presented.

• Substance K.  // Encyclopedic Reference of Molecular Pharmacology;2004, p890 

  An encyclopedia entry for Substance K is presented.

• Did you know...  // Tufts University Health & Nutrition Letter;May98, Vol. 16 Issue 3, p8 

  Reveals the gastrointestinal tract's measurement if it were stretched straight.

• Laxatives rarely needed. Cummings, M. // FDA Consumer;Apr91, Vol. 25 Issue 3, p33 

  Reports that laxatives can pose the risk of side effects and habituation. Avoiding quick fix laxatives; Description of several laxatives and how they work; Lifestyle changes to alleviate constipation; Adverse effects. INSET: Types of laxatives..

Read the Article